Episode 497: Reflections on the capivasertib ODAC
From The Uromigos · · 21 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.